- Home
- BANR vs MIRM Comparison
BANR vs MIRM Comparison
Compare BANR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANR | MIRM |
|---|---|---|
| Founded | 1890 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 5.7B |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BANR | MIRM |
|---|---|---|
| Price | $62.60 | $102.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $70.00 | ★ $119.85 |
| AVG Volume (30 Days) | 227.3K | ★ 847.5K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | 15.57 | ★ 74.59 |
| EPS | ★ 1.60 | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $0.73 | $26.22 |
| Revenue Next Year | $5.69 | $22.04 |
| P/E Ratio | $39.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.05 | $42.89 |
| 52 Week High | $69.83 | $114.99 |
Technical Indicators
Market Signals| Indicator | BANR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 51.75 |
| Support Level | $61.24 | $87.26 |
| Resistance Level | $63.08 | $107.51 |
| Average True Range (ATR) | 1.41 | 6.60 |
| MACD | -0.52 | 0.47 |
| Stochastic Oscillator | 2.64 | 51.68 |
Price Performance
Historical ComparisonAbout BANR Banner Corporation
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho, and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.